Haplotype Structure of the ENPP1 Gene and Nominal Association of the K121Q Missense Single Nucleotide Polymorphism With Glycemic Traits in the Framingham Heart Study by Stolerman, Elliot S. et al.
 
Haplotype Structure of the ENPP1 Gene and Nominal
Association of the K121Q Missense Single Nucleotide
Polymorphism With Glycemic Traits in the Framingham Heart
Study
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Stolerman, Elliot S., Alisa K. Manning, Jarred B. McAteer,
Josée Dupuis, Caroline S. Fox, L. Adrienne Cupples, James B.
Meigs, and Jose C. Florez. 2008. Haplotype Structure of the
ENPP1 Gene and Nominal Association of the K121Q Missense
Single Nucleotide Polymorphism With Glycemic Traits in the
Framingham Heart Study. Diabetes 57(7): 1971-1977.
Published Version doi:10.2337/db08-0266
Accessed February 19, 2015 4:27:45 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:4745730
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAAHaplotype Structure of the ENPP1 Gene and Nominal
Association of the K121Q Missense Single Nucleotide
Polymorphism With Glycemic Traits in the Framingham
Heart Study
Elliot S. Stolerman,
1,2,3 Alisa K. Manning,
4 Jarred B. McAteer,
1,2 Jose ´e Dupuis,
4 Caroline S. Fox,
5,6
L. Adrienne Cupples,
4 James B. Meigs,
3,7 and Jose C. Florez
1,2,3
OBJECTIVE—A recent meta-analysis demonstrated a nominal
association of the ectonucleotide pyrophosphatase phosphodies-
terase 1 (ENPP1)K 3Q missense single nucleotide polymor-
phism (SNP) at position 121 with type 2 diabetes. We set out to
conﬁrm the association of ENPP1 K121Q with hyperglycemia,
expand this association to insulin resistance traits, and deter-
mine whether the association stems from K121Q or another
variant in linkage disequilibrium with it.
RESEARCH DESIGN AND METHODS—We characterized the
haplotype structure of ENPP1 and selected 39 tag SNPs that
captured 96% of common variation in the region (minor allele
frequency 5%) with an r
2 value 0.80. We genotyped the SNPs
in 2,511 Framingham Heart Study participants and used age- and
sex-adjusted linear mixed effects (LME) models to test for
association with quantitative metabolic traits. We also examined
whether interaction between K121Q and BMI affected glycemic
trait levels.
RESULTS—The Q allele of K121Q (rs1044498) was associated
with increased fasting plasma glucose (FPG), A1C, fasting insu-
lin, and insulin resistance by homeostasis model assessment
(HOMA-IR; all P  0.01–0.006). Two noncoding SNPs (rs7775386
and rs7773477) demonstrated similar associations, but LME
models indicated that their effects were not independent from
K121Q. We found no association of K121Q with obesity, but
interaction models suggested that the effect of the Q allele on
FPG and HOMA-IR was stronger in those with a higher BMI (P 
0.008 and 0.01 for interaction, respectively).
CONCLUSIONS—The Q allele of ENPP1 K121Q is associated
with hyperglycemia and insulin resistance in whites. We found an
adiposity-SNP interaction, with a stronger association of K121Q
with diabetes-related quantitative traits in people with a higher
BMI. Diabetes 57:1971–1977, 2008
E
ctonucleotide pyrophosphatase phosphodiester-
a s e1( ENPP1), also known as plasma cell
membrane glycoprotein 1 (PC-1), is a transmem-
brane glycoprotein that down-regulates insulin
signaling in cells by inhibiting the tyrosine kinase activity
of the insulin receptor, perhaps by interaction with its
-subunit (1). Within the coding region of ENPP1,aK 3Q
missense single nucleotide polymorphism (SNP) at posi-
tion 121 (K121Q; rs1044498) has been previously associ-
ated with insulin resistance and related abnormalities in
some studies (2–7). The molecular mechanism thought to
be responsible for the role of the Q121 variant is a “gain of
function” of the ENPP1 protein inhibitory activity on the
insulin receptor (8). It has also been reported that insulin
receptor autophosphorylation in ﬁbroblasts is decreased
in Q allele carriers compared with KK homozygotes (2).
Thus, the ENPP1 gene is considered to be a likely candi-
date gene for insulin resistance and type 2 diabetes (9).
Multiple studies have shown both positive and negative
evidence of association between variants in ENPP1 and
obesity, type 2 diabetes, and related traits. Most recently,
Meyre et al. (5) found that a haplotype formed by three
SNPs in ENPP1 (one of which was K121Q) was associated
with childhood and adult obesity and type 2 diabetes.
Three subsequent large association studies of variants in
ENPP1 detected no association of ENPP1 K121Q with
type 2 diabetes or obesity: Grarup et al. (10) found no
association of K121Q with type 2 diabetes in a Danish
population; Lyon et al. (11) found no signiﬁcant associa-
tion between three ENPP1 SNPs (K121Q, rs1799774, and
rs7754561) and BMI or type 2 diabetes; and Weedon et al.
(12) found no association with variants in ENPP1 and type
2 diabetes or obesity in a study involving 8,089 subjects in
the U.K. In a comprehensive meta-analysis, we have re-
cently shown that the ENPP1 K121Q variant confers a
modestly increased risk of type 2 diabetes under a reces-
sive genetic model in whites (P  0.005), an effect that
appears to be modulated by BMI (13). Although these
studies were informative, only a handful of SNPs were
genotyped, and common variation in the ENPP1 locus has
not been examined comprehensively. Given the conﬂicting
body of evidence in the literature and incomplete evalua-
tion of the ENPP1 gene, we set out to conﬁrm the
association of ENPP1 K121Q with hyperglycemia, expand
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DIABETES, VOL. 57, JULY 2008 1971the characterization of this association to quantitative
insulin-related traits, assess the effect of adiposity on these
associations, and determine whether the association
stems from K121Q or another variant in linkage disequi-
librium with it.
RESEARCH DESIGN AND METHODS
Population samples. We used data from the Framingham Heart Study (FHS)
to study associations between ENPP1 variants and quantitative glycemic
traits. The FHS is a community-based, multigenerational, longitudinal study of
cardiovascular disease and its risk factors, including diabetes. The FHS
comprises the original cohort, offspring, and generation 3 studies. Subjects
described in the present analysis include 2,511 individuals from the FHS
offspring cohort. In this analysis, our principal diabetes-related quantitative
traits come from offspring examination 5 (1991–1994), where data from a 75-g
oral glucose tolerance test (OGTT) is available for all offspring without
diagnosed diabetes. The study was approved by Boston University’s institu-
tional review board, and written informed consent, including consent for
genetic analyses, was obtained for all study participants. The demographic
characteristics of the FHS study population are presented in Table 1.
An extensive array of diabetes-related quantitative traits has been collected
in the FHS. Diabetes-related quantitative traits measured in this study include:
A1C, fasting plasma glucose (FPG), fasting insulin, insulin resistance by
homeostasis model assessment (HOMA-IR), percent -cell function by ho-
meostasis model assessment (HOMA-B) (14), Gutt’s 0- to 120-min insulin
sensitivity index (15), and the time-averaged mean FPG level over exams 3–7
comprising 16 years (mean FPG). Laboratory methods for all quantitative
traits have been described previously (16).
We used 2003 American Diabetes Association clinical criteria to deﬁne
diabetes, where a case was deﬁned as use of oral hypoglycemic or insulin
therapy or a FPG 7.0 mmol/l at the index exam and 7.0 mmol/l on at least
one prior exam.
SNP selection. We targeted a genomic region from 20 kb upstream to 10
kb downstream of ENPP1. We ﬁrst downloaded Phase 2 HapMap (www.hap-
map.org) genotypes for the CEU population (accessed January 2006). We
genotyped the previously reported non-HapMap SNP rs1799774 in the HapMap
CEU samples to include it in its haplotype structure. We examined these 167
HapMap SNPs in Haploview (http://www.broad.mit.edu/edu/mpg/haploview/)
and found that 95 passed quality control ﬁlters, including genotyping call rate
75%, Hardy-Weinberg equilibrium (P  0.001), and absence of Mendelian
errors. We attempted to capture all remaining working variants with minor
allele frequency (MAF) 5% using Tagger (http://www.broad.mit.edu/mpg/
tagger/), using a pairwise approach, setting an r
2  0.8, and forcing in the
three previously reported SNPs (K121Q, rs1799774, and rs7754561). This
procedure yielded 39 SNPs tagging the region, including rs1799774. We
genotyped these 39 SNPs (and an additional SNP, rs7773477, whose MAF is
4.5% in Framingham and is located at the 3 intron-exon junction of exon 2) in
the FHS samples. Because seven SNPs failed genotyping in these initial FHS
samples, we repeated the tagging procedure forcing in all successful 32 SNPs
as tags: this yielded seven new SNPs, which were genotyped in the FHS
samples for a total of 40 SNPs (39 tags and rs7773477).
Genotyping. Genotyping was performed by allele-speciﬁc primer extension
of multiplex-ampliﬁed products with detection by matrix-assisted laser de-
sorption ionization–time of ﬂight mass spectroscopy on an iPLEX Sequenom
platform. Average genotyping call rates were 97.7%, the minimum call rate was
94.7%, and the average consensus rate based on 254 duplicate samples was
99.5%.
Statistical analysis. The quantitative traits were regressed against covari-
ates in order to produce Studentized residuals. Two models were used: the
ﬁrst with sex, age, and age
2 covariate adjustment, and the second added BMI
(kg/m
2) to the other covariates to examine the strength of the subsequent SNP
associations when adjusted for obesity. We adjusted for both age and age
2 to
allow for a nonlinear trend over time. The covariates from offspring exam 5
were used for all the traits except for mean FPG, for which we used the
16-year average of each covariate.
The association between each residual and each SNP was assessed using a
linear mixed effects (LME) model implemented in SOLAR (17) to account for
the within-family correlation. Each SNP was included in a model as a ﬁxed
effect with additive coding, although additional dominant and recessive
coding were evaluated to examine the association of rs1044498 (K121Q) with
the quantitative traits. The models included random effects to account for the
covariance between family members; the covariance structure was deter-
mined by the degree of relatedness between each relative pair (17).
The role of BMI in the association between rs1044498 (K121Q) and the
quantitative traits was further examined in LME models of the age-, age
2-, and
sex-adjusted residual with K121Q, BMI, and an interaction term between
K121Q and BMI as covariates.
To assess the association of each SNP with the type 2 diabetes phenotype,
we used Cox proportional hazards survival analysis with diabetes as the
outcome and the survival time as the age at the exam in which diabetes was
determined. The survival time of individuals without diabetes was the age at
their last exam. The model was implemented with the survival package in R
(18), with the same adjustments as in the LME models with covariates taken
at the ﬁrst exam. Trait correlation among siblings was modeled with a frailty
term in the survival model (19).
To assess whether positive association signals were due to linkage
disequilibrium with K121Q or were independent, we added the SNPs to LME
models already containing K121Q. If the signals were independent of K121Q,
we expected that they would remain signiﬁcant in these models. Alternatively,
if both K121Q and the other SNPs became nonsigniﬁcant, we would conclude
that the signal in the other SNPs was not independent from K121Q.
Our study was formulated around a single primary hypothesis: we intended
to replicate the association of K121Q with hyperglycemia as captured by
diabetes-related traits and, if such association was conﬁrmed, perform further
covariate adjustment for improved characterization and additional ﬁne-
mapping to determine the true source of the association signal. We have thus
tested a unique SNP for association with several components of one compos-
ite trait (hyperglycemia), which is reﬂected in multiple correlated measures.
We believe this primary hypothesis should not be seen as making multiple
unrelated comparisons, and we therefore chose a nominal P value of 0.05 to
indicate statistical signiﬁcance.
RESULTS
A linkage disequilibrium plot showing the completed hap-
lotype structure of the ENPP1 locus is presented in the
Supplemental Figure in the online appendix, which is
available at http://dx.doi.org/10.2337/db08-0266. The
ENPP1 gene region contains a high degree of linkage
disequilibrium. From the initial set of 167 SNPs, 96% of the
95 common variants with a MAF 5% were captured with
an r
2 value 0.8 (and 100% with an r
2 value 0.7) by a set
of 39 tag SNPs using single-marker (pairwise) tests. The
list of the 39 successful tag SNPs used in this analysis, with
chromosomal position, major allele, and MAF in both the
HapMap and Framingham population, is presented in
Table 2. The list of 95 captured SNPs with their tags is
listed in the online appendix (Supplemental Table 1).
We examined whether individual SNPs in ENPP1 were
associated with hyperglycemic and insulin resistance
traits in the FHS population. We ﬁrst focused our attention
on our principal polymorphism of interest, rs1044498
TABLE 1
Demographic characteristics of the FHS participants
Trait n
Mean  SD or
%
Age at exam 5 (years) 2,397 54.1  9.76
Sex (% women) 2,511 53.0
Type 2 diabetes 2,511 9.6
Mean BMI (kg/m
2) 2,387 27.4  4.95
Exam 5 FPG (mg/dl) 2,365 100.2  26.4
Exam 5 A1C (%) 1,745 5.4  0.97
Mean FPG (mg/dl) 2,510 99.4  20.42
Exam 5 fasting insulin (U/ml) 2,258 30.0  12.27
Exam 5 HOMA-IR 2,258 7.7  4.91
Exam 5 Gutt insulin sensitivity index 2,146 25.7  7.47
Exam 5 waist circumference
(inches) 2,394 36.5  5.65
Exam 5 HOMA-B -cell secretion 2,258 339.7  269.96
Unrelated participants 1,436 —
Pedigrees 282 —
Sibpairs 1,004 —
Avuncular pairs 114 —
Cousin pairs 632 —
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dominant, and recessive. Table 3 presents mean trait levels
for each genotypic group, with P values for association
with K121Q before and after adjustment for BMI. Several
associations with insulin resistance traits reached nominal
levels of signiﬁcance: speciﬁcally, under the additive
model, the Q allele was associated with higher FPG (P 
0.01), A1C (P  0.006), fasting insulin (P  0.006), and
HOMA-IR (P  0.006); all of these associations remained
signiﬁcant after adjusting for BMI. Similar P values were
obtained under the dominant genetic model. In this popu-
lation sample, there were no differences in mean trait
value across genotypic groups at ENPP1 K121Q for BMI
(P  0.32) or waist circumference (P  0.64), both tested
as continuous traits. When we compared the distribution
of genotypes at this locus across individuals who were of
normal weight (BMI 	25 kg/m
2), overweight (BMI 25–30
kg/m
2), or obese (BMI 30 kg/m
2), we found no associa-
tion of K121Q with obesity as a categorical trait (P  0.66).
We also found no signiﬁcant deviation from the null
hypothesis of no association when our cohort was divided
by BMI cutoffs at 25, 30, and 35 kg/m
2 (data not shown).
We then explored whether these consistent associations
might be driven by other polymorphisms in the region.
Table 4 displays the ENPP1 SNPs for which we detected
nominally signiﬁcant associations with any of the glycemic
traits under study. Figure 1A (glucose-related traits) and B
(insulin-related traits) display the P values for rs1044498
(K121Q) in comparison with those obtained for other
SNPs across the genomic segment. Although K121Q was
the SNP that showed the strongest association with fasting
insulin and HOMA-IR (Fig. 1B), two other SNPs (rs7775386
and rs7773477, located in intron 1 and at the exon 2-intron
2 junction, respectively) achieved similar P values for
associations with FPG and A1C; these two SNPs were also
nominally associated with HOMA-IR (Table 4). To deter-
mine whether the effects of rs7775386 and rs7773477 were
independent from K121Q or produced an association
signal simply because they are in tight linkage disequilib-
rium with K121Q, we calculated the r
2 among those SNPs
TABLE 2
Tag SNPs genotyped in the FHS sample
SNP Position (NCBI 35)
CEU FHS
M/m MAF M/m MAF
rs7752279 132154028 G/A 0.42 G/A 0.44
rs9493099 132155096 T/C 0.27 T/C 0.29
rs9493100 132156774 C/T 0.09 C/T 0.10
rs13211931 132165417 G/T 0.05 G/T 0.05
rs11154643 132166495 C/G 0.07 C/G 0.06
rs6935458 132168013 A/G 0.11 A/G 0.11
rs6569759 132174809 A/G 0.50 G/A 0.48
rs943004 132182569 G/A 0.06 G/A 0.07
rs7756163 132184356 T/C 0.39 T/C 0.38
rs12201710 132184591 G/A 0.22 G/A 0.25
rs1409182 132185636 G/A 0.16 G/A 0.12
rs9402345 132185906 G/A 0.10 G/A 0.11
rs9375830 132188213 G/A 0.22 G/A 0.20
rs6917903 132189309 G/C 0.38 G/C 0.42
rs1409181 132190993 G/C 0.48 C/G 0.47
rs2021966 132192132 T/C 0.44 T/C 0.46
rs9372999 132194845 C/A 0.10 C/A 0.12
rs858338 132194900 G/T 0.21 G/T 0.18
rs858339 132195590 T/A 0.32 T/A 0.29
rs703184 132196688 C/G 0.15 C/G 0.13
rs7775386 132198842 C/T 0.15 C/T 0.16
rs6916495 132201958 C/T 0.11 C/T 0.12
rs858342 132202336 A/G 0.27 A/G 0.25
rs858345 132205310 A/G 0.43 A/G 0.42
rs4141767 132206700 A/G 0.07 A/G 0.11
rs9402348 132209369 T/G 0.28 T/G 0.24
rs1044498* 132214061 A/C 0.12 A/C 0.17
rs9402349 132226801 A/C 0.12 A/C 0.12
rs9493116 132242326 A/G 0.05 A/G 0.07
rs7768480 132245125 A/G 0.06 A/G 0.11
rs1799774 132245167 T/del 0.33 T/del 0.25
rs7767111 132249978 G/A 0.09 G/A 0.06
rs1974201 132252814 C/G 0.10 C/G 0.23
rs7754561 132254387 A/G 0.20 A/G 0.28
rs9493120 132254694 G/A 0.06 G/A 0.06
rs9493121 132254883 A/G 0.09 A/G 0.05
rs1510 132256615 G/C 0.15 G/C 0.12
rs7753048 132259380 C/T 0.10 C/T 0.12
rs9373000 132263399 A/G 0.19 A/G 0.28
Data are position, major (M) and minor (m) nucleotides, and MAFs for all 39 tag SNPs for HapMap (CEU) and Framingham (FHS)
populations. *K121Q SNP.
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2 between
K121Q and rs7775386 was 0.664, and between K121Q and
rs7773477 was 0.285 (Table 4); however, given the high
degree of relatedness within FHS pedigrees, these linkage
disequilibrium measures obtained from unrelated partici-
pants may be an underestimation of the true correlation
between SNPs within the analytic dataset, where, among
related people, large chromosomal regions are expected to
be identical by descent. We therefore also used LME
models to examine simultaneously the effects of the three
strongest association signals (K121Q, rs7773477, and
rs7775386). Although the association of rs7773477 with
FPG remained nominally signiﬁcant after addition of
rs7775386 to the model, statistical signiﬁcance disap-
peared after inclusion of K121Q to models that contained
either rs7773477 or rs7775386. This indicates that the
associations of these SNPs with diabetes-related quantita-
tive traits are likely accounted for by their linkage disequi-
librium with K121Q and that the latter is giving the
strongest common variant association signal in the region.
Supplemental Table 2 lists all the data for each polymor-
phism and quantitative traits examined. There was no
signiﬁcant association between any variant in ENPP1 and
BMI or waist circumference. There was no signiﬁcant
relationship between the non-HapMap SNP rs1799774
(which codes for a T/del change) and any insulin resis-
tance trait. Other than a nominal P value of 0.02 for
rs7775386, there was no signiﬁcant association between
K121Q or any other variant and risk for incident diabetes.
Finally, we also examined the interaction between
K121Q and BMI because of preliminary evidence suggest-
ing that the effect of the Q allele may be modiﬁed by an
increase in adiposity. There was a nominally signiﬁcant
interaction between genotype at ENPP1 K121Q and BMI
for the associations of the SNP with FPG (interaction P
value  0.008,  estimate  0.017) and HOMA-IR (inter-
TABLE 3
Association between rs1044498 (K121Q) and diabetes-related quantitative traits
Trait KK KQ QQ
Percent
variance
explained
P value
Additive Recessive Dominant
n 1,982 695 74
FPG (mg/dl) 99  23.9 101  29.6 107  43.0 0.17 (0.11) 0.01 (0.02) 0.07 (0.16) 0.02 (0.03)
A1C (%) 5.39  0.93 5.48  1.02 5.72  1.24 0.40 (0.30) 0.006 (0.01) 0.03 (0.03) 0.02 (0.03)
Mean FPG (mg/dl) 99.1  19.92 99.6  21.23 101  21.5 0.005* 0.21 (0.26) 0.42 (0.63) 0.25 (0.27)
Fasting insulin (U/ml) 29.5  11.57 31.3  13.87 31.2  12.09 0.32 (0.22) 0.006 (0.01) 0.58 (0.96) 0.003 (0.006)
HOMA-IR 7.5  4.71 8.06  5.43 8.05  4.37 0.29 (0.19) 0.006 (0.01) 0.56 (0.95) 0.004 (0.005)
HOMA-B 343.8  179.4 329.1  444.7 336.8  136.6 0.04 (0.03) 0.40 (0.49) — —
Gutt’s ISI 25.8  7.36 25.4  7.76 26.3  7.42 0.03 (0.01) 0.31 (0.42) 0.29 (0.15) 0.12 (0.15)
Waist circumference
(inches) 36.5  5.55 36.4  5.93 37.6  6.01 0.02 (0.04) 0.64 (0.35) 0.43 (0.93) 0.80 (0.30)
BMI (kg/m
2) 27.4  4.83 27.5  5.19 28.4  6.26 0.06 0.32 0.42 0.40
All quantitative trait values are unadjusted means  SD, with P values without parentheses adjusted for sex and age and P values in
parentheses additionally adjusted for BMI. Associations between rs1044498 (K121Q) and selected quantitative metabolic traits in the FHS,
with P values for the additive, recessive, and dominant genetic models are shown. The major (A) and minor (C) alleles code for the amino
acids lysine (K) and glutamine (Q), respectively. The MAF is 15% in Framingham. Mean FPG, FPG averaged over exams 3–7 comprising 16
years; Gutt’s ISI, Gutt’s insulin sensitivity index. *The variance due to K121Q was not estimable because of instability.
TABLE 4
Nominally signiﬁcant associations (P 	 0.05) of selected ENPP1 SNPs with diabetes-related quantitative traits
SNP (MM/Mm/mm)
Alleles
(M/m) MAF r
2 Trait MM Mm mm P value
rs7752279 (926/1,343/528) G/A 0.43 0.106 A1C 5.38  0.89 5.42  0.95 5.53  1.14 0.01 (0.02)
rs9493099 (1,375/1,164/225) T/C 0.29 0.026 A1C 5.4  0.94 5.43  0.98 5.55  1.09 0.046
Fasting insulin 30.3  12.15 29.9  12.46 29.4  12.37 (0.046)
rs13211931 (2,540/224/6) G/T 0.04 0.063 Fasting insulin 29.9  11.96 31.8  15.34 34.7  11.1 0.04
rs7775386 (2,031/642/55) C/T 0.14 0.664 FPG 99  23.4 102  33.1 103  35.5 0.005 (0.004)
A1C 5.39  0.9 5.53  1.16 5.64  1.05 0.004 (0.005)
Mean FPG 98.8  19.56 100.9  23.16 99.7  20.67 0.03 (0.02)
HOMA-IR 7.5  4.78 8  5.4 7.8  4.12 0.04 (0.03)
rs4141767 (2,230/489/34) A/G 0.10 0.591 Fasting insulin 29.7  11.71 31.3  14.23 32.6  13.07 0.02
rs7773477 (2,509/235/7) G/T 0.05 0.285 FPG 99  24.8 106  40.8 103  13.6 0.002 (0.001)
HOMA-IR 7.6  4.94 8.1  4.94 8.8  4.17 (0.04)
rs9493116 (2,377/343/20) A/G 0.07 0.410 A1C 5.41  0.95 5.56  1.15 5.58  0.54 0.03 (0.04)
rs1510 (2,105/608/30) G/C 0.12 0.026 A1C 5.45  1 5.33  0.85 5.75  1.16 (0.048)
All quantitative trait values are crude means  SD, with P values without parentheses adjusted for sex and age and P values in parentheses
additionally adjusted for BMI. Associations between SNPs (listed in order of increasing chromosomal position, with genotype counts in
parentheses following the rs number) and phenotypic traits that had nominal P values 	0.05 using an additive genetic model are shown. The
MAFs are based on data from FHS unrelated participants. The extent of linkage disequilibrium of each SNP in relation to rs1044498 (K121Q)
is shown by presenting r
2 values obtained from the unrelated subset of our FHS sample. M, major allele; m, minor allele; mean FPG, FPG
averaged over exams 3–7 comprising 16 years.
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a stronger genetic association of the Q allele with insulin
resistance traits among people who have a higher BMI.
DISCUSSION
The association of the K121Q polymorphism in ENPP1
with insulin resistance and type 2 diabetes has been
controversial. Regarding insulin resistance, Pizzuti et al.
(2) found that nonobese, nondiabetic Q allele carriers
were more insulin resistant than KK homozygotes, as
deﬁned both by OGTT and the euglycemic clamp. Subse-
quent studies reported both positive (20) and negative
evidence (10) of association with insulin resistance. For
type 2 diabetes, an initial positive result of association by
Pizzuti et al. (2) was followed by replication in several
independent studies (3–5) and conﬁrmation in partial
meta-analyses (10,12,21); however, three very large asso-
ciation studies (including one by members of our group)
that comprised several thousand samples in other popula-
tions of European descent failed to reproduce the associ-
ation, despite apparently adequate power to do so (10–12).
In addition, ﬁve high-density genome-wide association
studies (in samples that partially overlap those studied
previously) have not reported a robust association at this
locus (22–26). Nevertheless, a recent comprehensive meta-
analysis by members of our group (13) documented a
nominally signiﬁcant (P  0.005) association of the K121Q
QQ genotype with type 2 diabetes in populations of
European ancestry under a recessive model. The associa-
tion appeared to be modiﬁed by BMI. The very modest
effect of a single Q allele on the diabetes phenotype
(summary odds ratio 1.08), the initial overestimation of
this risk due to the phenomenon of the “winner’s curse,”
the lack of power of subsequent studies to explore alter-
native genetic models, the confounder introduced by the
widely divergent allele frequencies of the K121Q poly-
morphism in European and African populations, and the
noninclusion of a relevant covariate (BMI) in the assess-
ment of its contribution to diabetes risk may explain, in
part, the conﬂicting results thus far reported in the
literature.
Given the new evidence suggesting a real association of
this polymorphism with type 2 diabetes and functional
reports implicating ENPP1 and its polymorphism K121Q in
mechanisms of insulin resistance (1,8,27–29), we decided
to examine its association with insulin resistance traits in
a homogeneous population cohort previously unexamined
for this variant. In addition, we aimed to determine
whether any association, if present, stemmed from ENPP1
K121Q or another polymorphism in the region, and we
aimed to characterize the putative modifying effect of BMI.
The Framingham offspring cohort is particularly advanta-
geous for such a study: 1) As a population cohort, it is free
of ascertainment biases, which may restrict the range of
variation around a quantitative glycemic or obesity trait; 2)
it is an ethnically homogeneous sample; 3) it has under-
gone extensive phenotypic characterization in a longitudi-
nal fashion; and 4) its family component reduces the risk
of population stratiﬁcation.
In this study, we captured most of the common genetic
variation in ENPP1 and studied its putative association
with glycemic traits in a comprehensive manner. Using the
FHS population to characterize the common variation
across the ENPP1 locus, we conﬁrmed the association of
the Q allele in ENPP1 K121Q with hyperglycemia, as
demonstrated by elevated FPG and A1C, under both the
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FIG. 1. A: Negative log base 10 of the P value for genetic associations with FPG (circles) and glycated hemoglobin (diamonds) under the additive
model (left y-axis) graphed versus SNPs in the ENPP1 region arranged by chromosomal position (x-axis). The continuous line marked by the right
y-axis indicates the recombination rate. The ENPP1 gene is shown by the horizontal arrow at the bottom of the plot. Open symbols indicate traits
adjusted for sex and age; closed symbols indicate additional adjustment for BMI. B: Negative log base 10 of the P value for genetic associations
with fasting insulin (circles) and insulin resistance by HOMA (diamonds) under the additive model (left y-axis) graphed versus SNPs in the
ENPP1 region arranged by chromosomal position (x-axis). The continuous line marked by the right y-axis indicates the recombination rate. The
ENPP1 gene is shown by the horizontal arrow at the bottom of the plot. Open symbols indicate traits adjusted for sex and age; closed symbols
indicate additional adjustment for BMI.
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esis that only one copy of the Q allele is necessary to cause
an effect on quantitative phenotypes. We also demon-
strated that the effect of K121Q on hyperglycemia is likely
mediated via insulin resistance, because the Q allele is also
associated with elevated fasting insulin and HOMA-IR. The
lack of an association with the Gutt insulin sensitivity
index may reﬂect differences in insulin resistance at the
tissue level (basal hepatic insulin resistance vs. peripheral
glucose disposal after an oral load) or indicate an imper-
fect correlation of these surrogate measures with true
insulin resistance. Although other polymorphisms in the
region showed similar associations with glycemic traits,
our regression analysis demonstrated that the effect of two
other signiﬁcant SNPs was removed when incorporating
K121Q in the models, suggesting that K121Q is the variant
with the actual effect on glycemic and insulin resistance
traits, as might be predicted by its impact on amino acid
sequence. Because these associations represent conﬁrma-
tion of previous ﬁndings and other variants in the region
were genotyped as a ﬁne-mapping exercise, we do not
believe statistical correction for the multiple variants
analyzed is warranted.
Having established the association between ENPP1
K121Q and hyperglycemia, we explored the interaction
between K121Q and BMI because of preliminary evidence
that the effect of the Q allele on glycemic traits is mediated
by an increase in adiposity (3,5,7,13,30) and suggestions
that this variant may also contribute to obesity traits
(5,6,31–33). Although we observed no association of
ENPP1 K121Q with BMI or waist circumference, our
interaction analysis supports the observation that a higher
BMI strengthens the association of this particular poly-
morphism with elevated insulin resistance and glucose
levels. This ﬁnding is consistent with the hypothesis that
the net effect of the ENPP1 Q121 variant in modulating the
risk of insulin resistance and related clinical outcomes is
barely detectable in lean individuals while becoming more
evident in the context of an “obesogenic” background,
where the deleterious effect of the Q121 variant on the
glucose disposal of skeletal muscle may be superimposed
on that exerted by high BMI itself (30). This model is
consistent with our previous meta-analysis in which we
noted that the Q121 variant confers a modest risk of type
2 diabetes in whites with a greater effect as BMI increases.
Such BMI 
 genotype interactions may be particularly
evident with regard to genes that cause hyperglycemia by
augmenting insulin resistance rather than in those that
contribute to diabetes risk by diminishing insulin secre-
tion. Because of the relationship between obesity and
insulin resistance, there is more likely to be a correlation
between increased adiposity and the effects of genes that
modify insulin action.
In summary, our study adds further evidence in
support of a potential causative role of the ENPP1 gene
in the inheritance and pathophysiology of type 2 diabe-
tes. We found that the Q allele of K121Q in ENPP1
appears to be the common variant most strongly asso-
ciated with diabetes-related traits in whites, conﬁrmed
that K121Q is associated with hyperglycemia and a
greater degree of insulin resistance, and found an
adiposity-SNP interaction, with a greater strength of
association of K121Q with diabetes-related quantitative
traits in people with obesity.
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